Details of the Drug

General Information of Drug (ID: DMCVJ86)

Drug Name
Clofarabine
Synonyms
CAFdA; CFB; Clofarabina; Clofarabinum; Clofarex; Clolar; Evoltra; Clofarabine [USAN]; Clolar (TN); Evoltra (TN); Clofarabine (USAN/INN); Clolar, Evoltra, Clofarabine; Cl-F-Ara-A; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 3S211048
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
Acute myelogenous leukaemia 2A41 Approved [2]
Langerhans cell histiocytosis N.A. Approved [2]
Leukemia N.A. Approved [2]
Myelodysplastic syndrome 2A37 Approved [1]
Plasma cell myeloma 2A83.1 Approved [2]
Classic Hodgkin lymphoma N.A. Investigative [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01BB06: Clofarabine
L01BB: Purine analogues
L01B: ANTIMETABOLITES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 303.68
Logarithm of the Partition Coefficient (xlogp) 0.9
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.7 mL/min/kg [4]
Elimination
55% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 5.2 hours [4]
Metabolism
The drug is metabolized via the deoxycytidine kinase and mono- and di-phosphokinases []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.234 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.53% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.75 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 1 mg/mL [3]
Chemical Identifiers
Formula
C10H11ClFN5O3
IUPAC Name
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
Canonical SMILES
C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N
InChI
InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
InChIKey
WDDPHFBMKLOVOX-AYQXTPAHSA-N
Cross-matching ID
PubChem CID
119182
ChEBI ID
CHEBI:681569
CAS Number
123318-82-1
UNII
762RDY0Y2H
DrugBank ID
DB00631
TTD ID
D0R5RR
VARIDT ID
DR01330
INTEDE ID
DR1773
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Binder [6]
Ribonucleotide reductase (RIR) TTX09M4 RIR1_HUMAN ; RIR2_HUMAN ; RIR2B_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Equilibrative nucleoside transporter 2 (SLC29A2) DTW78DQ S29A2_HUMAN Substrate [7]
Equilibrative nucleoside transporter 1 (SLC29A1) DTXD1TQ S29A1_HUMAN Substrate [7]
Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3) DT4YL5R S28A3_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Deoxycytidine kinase (DCK)
Main DME 		DE9FGNK DCK_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [10]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 149 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 -6.0541 3.3378 -6.5307 70.5735
MEC1 CTRP2 -1.4085 8.5598 -2.8923 49.7638
JM1 CTRP2 -7.2837 -5.7028 -7.2837 88.352
SUP-T1 CTRP2 -12.4724 2.3512 -13.2882 81.8251
MOLM-6 CTRP2 -11.503 6.3371 -13.1863 76.1974
Mono-Mac-1 CTRP2 -11.4202 3.8076 -12.4543 79.025
PL21 CTRP2 -11.0985 -2.3781 -11.2028 88.1832
RCH-ACV CTRP2 -10.9973 -0.4976 -11.2601 84.8737
GDM-1 CTRP2 -10.847 8.5835 -13.1408 73.2321
Raji CTRP2 -10.763 9.6659 -13.4009 72.1711
Reh CTRP2 -10.7498 -6.7428 -10.7501 96.1236
RS4;11 CTRP2 -10.6567 -7.1592 -10.6568 96.6274
MHH-CALL-4 CTRP2 -10.5846 -1.0747 -10.7664 85.5163
OCI-AML-2 CTRP2 -10.4448 -7.3094 -10.4449 97.114
BV-173 CTRP2 -10.3028 -6.7544 -10.3029 96.1
HPB-ALL CTRP2 -9.8135 6.7847 -11.4695 73.6786
SUP-T11 CTRP2 -9.3573 10.0771 -12.0156 69.9626
TALL-1 [Human adult T-ALL] CTRP2 -9.1009 20.8886 -16.013 63.3301
697 CTRP2 -7.8632 -6.605 -7.8632 92.1351
JURL-MK1 CTRP2 -6.8743 -5.7805 -6.8743 86.0166
MV4-11 CTRP2 -6.7949 -5.5157 -6.7949 85.4455
NALM-6 CTRP2 -6.7161 -5.4182 -6.7161 84.9256
DoHH2 CTRP2 -6.6136 -5.1863 -6.6136 84.2153
SUP-B15 CTRP2 -6.6072 -5.4021 -6.6072 84.2375
Kasumi-2 CTRP2 -6.5982 -5.3609 -6.5982 84.1711
CML-T1 CTRP2 -6.4559 -5.9499 -6.4559 83.2785
WSU-DLCL2 CTRP2 -6.4545 -5.5077 -6.4545 83.2613
ALL-SIL CTRP2 -6.4221 -5.1416 -6.4221 83.0049
SU-DHL-8 CTRP2 -6.4046 2.2182 -6.7205 73.0517
P12-Ichikawa CTRP2 -6.3881 -5.7526 -6.3881 82.8265
DB CTRP2 -6.357 -3.3122 -6.3573 81.3131
EoL-1 CTRP2 -6.3534 -5.5583 -6.3534 82.5942
KO52 CTRP2 -6.3375 -5.6527 -6.3375 82.4897
HEL 92.1.7 CTRP2 -6.3042 -5.9134 -6.3042 82.268
JeKo-1 CTRP2 -6.3034 -5.68 -6.3034 82.2627
GA-10 CTRP2 -6.284 5.6502 -7.3043 68.4515
Mino CTRP2 -6.2022 -5.5564 -6.2022 81.5887
EM-2 CTRP2 -6.1603 -5.1815 -6.1603 81.3039
SET-2 CTRP2 -6.1349 -4.8679 -6.1349 81.112
Namalwa CTRP2 -6.097 -4.9237 -6.097 80.8713
RPMI-8402 CTRP2 -6.0283 -5.0543 -6.0283 80.4259
U-937 CTRP2 -6.0136 -3.5452 -6.0137 79.8104
CMK CTRP2 -6.0015 -5.3517 -6.0015 80.2516
KE-37 CTRP2 -5.9708 -4.6708 -5.9708 80.0221
A4/Fukuda CTRP2 -5.94 -4.5139 -5.94 79.8013
SEM CTRP2 -5.9171 -5.1096 -5.9171 79.6889
MOLT-16 CTRP2 -5.9 -4.7808 -5.9 79.5671
Granta-519 CTRP2 -5.8264 -4.6233 -5.8264 79.073
MOLT-3 CTRP2 -5.7998 -5.1652 -5.7998 78.9079
DND-41 CTRP2 -5.7591 -3.8551 -5.7591 78.496
NOMO-1 CTRP2 -5.6331 -3.7486 -5.6331 77.6812
MC116 CTRP2 -5.6305 3.9819 -6.1987 68.5736
OCI-Ly3 CTRP2 -5.5664 -4.0954 -5.5664 77.3254
M-07e CTRP2 -5.5586 -4.34 -5.5586 77.2928
SU-DHL-10 CTRP2 -5.4758 2.7916 -5.8125 69.5416
MOLT-13 CTRP2 -5.4545 -2.6446 -5.4548 76.078
MOTN-1 CTRP2 -5.3562 -3.301 -5.3562 75.8223
ME1 CTRP2 -5.336 14.2601 -9.2921 60.1302
NU-DHL-1 CTRP2 -5.3352 -4.5033 -5.3352 75.8126
JJN-3 CTRP2 -5.2852 3.8085 -5.7891 67.7169
AML-193 CTRP2 -5.256 -3.5686 -5.256 75.2445
HuNS1 CTRP2 -5.1972 -4.1114 -5.1972 74.8914
PF-382 CTRP2 -5.1635 -3.4729 -5.1635 74.6319
SU-DHL-4 CTRP2 -5.1553 -4.0548 -5.1553 74.6126
KMS-34 CTRP2 -5.1537 -4.2818 -5.1537 74.6031
KMS-26 CTRP2 -5.1362 -3.5913 -5.1362 74.4665
CA46 CTRP2 -5.0998 5.2826 -5.9183 65.5825
Ku812 CTRP2 -5.0615 -0.2111 -5.0902 71.7687
SIG-M5 CTRP2 -5.0231 -3.4975 -5.0231 73.7178
Ci-1 CTRP2 -4.9873 -2.8117 -4.9873 73.3771
OCI-Ly10 CTRP2 -4.9217 1.6325 -5.0691 68.9973
ST486 CTRP2 -4.8864 5.3807 -5.7103 64.8222
SKM-1 CTRP2 -4.8133 -3.0216 -4.8133 72.3022
THP-1 CTRP2 -4.8009 -3.6773 -4.8009 72.2517
MM1.S CTRP2 -4.7579 -3.9984 -4.7579 71.9663
Karpas-422 CTRP2 -4.7415 -2.2046 -4.7417 71.662
OCI-M1 CTRP2 -4.6265 -3.2399 -4.6265 71.087
L-540 CTRP2 -4.3358 -1.1212 -4.3382 68.7594
RL CTRP2 -4.289 43.9789 -22.0986 53.1835
MOLM-13 CTRP2 -4.1981 -2.9582 -4.1981 68.2364
P31/FUJ CTRP2 -4.0017 -2.8175 -4.0017 66.928
EB1 CTRP2 -3.9584 1.3784 -4.0362 64.9629
KYO-1 CTRP2 -3.8846 -0.707 -3.8876 65.8757
MOLM-16 CTRP2 -3.7892 -0.3595 -3.7949 65.1612
Karpas-299 CTRP2 -3.7696 -2.0734 -3.7696 65.3763
A3/Kawakami CTRP2 -3.6559 -1.8448 -3.6559 64.6162
HL-60 CTRP2 -3.292 -1.5842 -3.292 62.197
LAMA-84 CTRP2 -3.2627 -0.9746 -3.263 61.9773
Ri-1 CTRP2 -3.121 9.1531 -4.9512 56.4523
SUP-M2 CTRP2 -3.1208 -1.4457 -3.1208 61.0576
KE-97 CTRP2 -3.0951 -1.96 -3.0951 60.8886
KMS-21-BM CTRP2 -3.0647 -1.5569 -3.0647 60.6852
Kasumi-1 CTRP2 -3.0273 7.93 -4.4282 56.6119
JVM-3 CTRP2 -3.001 -1.608 -3.001 60.2613
TF-1 CTRP2 -2.9687 21.5953 -10.1036 53.2467
SU-DHL-6 CTRP2 -2.8838 -0.6626 -2.8841 59.4656
SU-DHL-1 CTRP2 -2.6576 -1.8735 -2.6576 57.9739
KM-H2 CTRP2 -2.604 0.3541 -2.6084 57.5523
DEL CTRP2 -2.5164 -1.9426 -2.5164 57.0331
Peer CTRP2 -2.4633 3.5893 -2.7036 55.8423
MOLP-2 CTRP2 -2.2663 0.3868 -2.2688 55.3441
Ki-JK CTRP2 -2.2453 -1.1098 -2.2453 55.2273
KHM-1B CTRP2 -2.2125 -0.4434 -2.2125 55.0075
NCO2 CTRP2 -2.1028 0.2156 -2.1037 54.2704
KMS-27 CTRP2 -2.0822 2.252 -2.1452 53.9571
L-428 CTRP2 -2.0589 0.496 -2.0611 53.9724
KMS-12-BM CTRP2 -2.0578 11.4853 -4.708 52.16
KMS-28BM CTRP2 -2.0481 4.3888 -2.3965 53.3498
HT CTRP2 -2.0044 4.9652 -2.4701 52.9986
AMO1 CTRP2 -2.0011 -0.4781 -2.0011 53.6001
EHEB CTRP2 -1.7849 0.0584 -1.785 52.1593
Hs 611.T CTRP2 -1.5738 3.6818 -1.764 50.6907
KMS-11 CTRP2 -1.521 7.1066 -2.5247 50.2984
RPMI-6666 CTRP2 -1.4948 0.3567 -1.495 50.2273
MOLP-8 CTRP2 -1.4206 0.2617 -1.4217 42.2007
BL-70 CTRP2 -1.4022 12.1626 -4.2987 49.7886
KCL-22 CTRP2 -1.3891 6.4217 -2.1741 49.6259
SK-MM-2 CTRP2 -1.3825 5.0219 -1.9633 46.5608
Daudi CTRP2 -1.2738 0.5424 -1.274 48.7549
L-363 CTRP2 -1.1389 1.6978 -1.1488 47.869
HH [Human lymphoma] CTRP2 -1.0996 16.298 -5.8033 48.9385
MHH-CALL-3 CTRP2 -1.0726 120.9018 -57.418 49.8255
KMS-20 CTRP2 -1.021 0.2652 -1.021 47.0708
NCI-H929 CTRP2 -0.9882 0.17 -0.9882 46.8522
HDLM-2 CTRP2 -0.9118 4.1949 -1.1339 46.6238
MJ CTRP2 -0.4175 3.4261 -0.5025 43.249
OPM-2 CTRP2 0.0148 5.1616 -0.3175 40.9824
HuT 78 CTRP2 0.065 3.2629 0.0179 39.9742
HD-MY-Z CTRP2 0.2852 3.9406 0.184 38.6684
Mono-Mac-6 CTRP2 0.755 58.2942 -24.6096 47.9003
EJM CTRP2 0.9033 3.9328 0.8386 34.4619
U266B1 CTRP2 0.9161 5.631 0.5549 35.2769
LP-1 CTRP2 1.682 11.9799 -1.0427 36.3758
SR CTRP2 1.82 3.0392 1.8194 28.1455
KMS-18 CTRP2 1.9456 11.8314 -0.7096 34.8969
F-36P CTRP2 1.9765 14.0675 -1.7124 36.7071
P3HR-1 CTRP2 2.0509 25.1576 -7.015 42.0544
RPMI-8226 CTRP2 3.8739 6.7252 3.4601 15.9475
Toledo CTRP2 3.9605 13.1673 0.6257 25.8973
SUP-HD1 CTRP2 3.9808 6.2122 3.7444 14.581
Pfeiffer CTRP2 4.0098 10.9727 1.7312 22.1319
OCI-AML-3 CTRP2 4.7566 6.3514 4.5446 9.3371
OCI-Ly19 CTRP2 5.1197 6.169 4.9987 6.5888
OCI-AML-5 CTRP2 6.0571 6.7761 5.689 1.4694
K-562 CTRP2 6.4389 16.023 1.38 18.0201
Karpas-620 CTRP2 7.5408 9.5006 5.3465 1.0175
KMM-1 CTRP2 8.1343 16.5292 2.4252 11.3339
BL-41 CTRP2 8.1928 20.7733 0.3847 18.0919
REC-1 CTRP2 8.9079 10.6235 5.4933 0.1312
⏷ Show the Full List of 149 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 -1.4297 2.0018 -1.4555 49.7968
TE8 CTRP2 6.7871 15.8234 1.7592 16.0405
TE-5 CTRP2 -0.2573 7.3409 -1.226 43.649
TE-4 CTRP2 0.2946 4.9136 0.0381 39.0166
TE-9 CTRP2 0.9585 5.9643 0.5157 35.2362
TE-14 CTRP2 1.8245 7.7351 0.8876 31.1831
OE21 CTRP2 2.3375 10.4798 0.2945 31.2855
EC-GI-10 CTRP2 2.4046 8.2474 1.3107 28.0203
KYSE-510 CTRP2 2.4813 10.228 0.5529 30.1327
KYSE-70 CTRP2 4.3781 11.5728 1.7928 21.0028
TE-10 CTRP2 5.081 12.3944 2.0347 18.4873
TE-6 CTRP2 5.3872 9.9632 2.8645 9.1154
TE-11 CTRP2 6.162 14.57 1.8792 16.7973
COLO 680N CTRP2 6.3947 16.0572 1.3268 18.2861
KYSE-140 CTRP2 7.1847 19.5644 0.2096 20.3341
OE19 CTRP2 7.4711 12.9965 3.6736 7.5011
KYSE-410 CTRP2 7.7352 15.0445 2.8638 10.2919
OE33 CTRP2 8.0216 16.5915 2.3141 11.9192
KYSE-520 CTRP2 8.2377 17.4151 2.0671 12.4811
KYSE-450 CTRP2 8.3168 14.0235 3.7524 6.0074
KYSE-150 CTRP2 8.887 22.0332 0.2775 17.3069
KYSE-180 CTRP2 9.4606 14.7583 4.0973 3.4796
TE-1 CTRP2 10.2033 18.6558 2.7752 7.3107
KYSE-30 CTRP2 13.3031 29.3847 -0.274 13.1106
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 7.141 16.1321 1.8828 14.9601
L3.3 CTRP2 -2.4941 0.2173 -2.4966 56.8498
KP-4 CTRP2 -1.1576 2.204 -1.1849 48.0104
PSN1 CTRP2 -1.1064 3.6754 -1.4737 40.8117
HuP-T4 CTRP2 -0.9352 7.8035 -2.1165 47.4223
YAPC CTRP2 -0.6223 8.3163 -1.9574 45.9457
Panc 03.27 CTRP2 -0.3462 2.7262 -0.4589 34.384
SUIT-2 CTRP2 1.2777 32.3849 -11.2825 45.2882
BxPC-3 CTRP2 1.7202 10.1291 -0.1873 34.4294
SW1990 CTRP2 2.2509 7.8099 1.3168 28.4709
MIA PaCa-2 CTRP2 2.5353 7.0244 1.9086 25.5761
DAN-G CTRP2 3.8853 11.7614 1.2342 24.1588
Capan-1 CTRP2 4.4972 12.2947 1.5518 21.5726
SU.86.86 CTRP2 5.0364 13.3382 1.5267 20.4177
Panc 10.05 CTRP2 5.3532 13.2551 1.848 18.5773
PaTu 8988t CTRP2 5.6333 6.7084 3.738 0.1559
KP-3 CTRP2 5.6759 14.2394 1.6359 18.6546
CFPAC-1 CTRP2 5.782 18.5797 -0.4432 24.8121
Panc 02.03 CTRP2 5.9213 10.8036 2.1071 6.1639
AsPC-1 CTRP2 6.2028 15.0817 1.6571 17.5144
Panc 04.03 CTRP2 6.2173 14.7921 1.8138 16.9258
Hs 766T CTRP2 6.2618 10.6371 3.9266 8.4849
Panc 05.04 CTRP2 6.4664 23.5416 -2.3551 27.8401
TCC-Pan2 CTRP2 6.6382 14.094 2.5032 13.5514
PK-45H CTRP2 6.9904 12.4353 3.599 8.5645
Panc 08.13 CTRP2 7.4097 14.047 3.1161 9.8221
QGP-1 CTRP2 7.5044 13.6043 3.4013 8.54
SNU-213 CTRP2 7.508 9.5591 5.3048 1.1777
HuP-T3 CTRP2 8.275 15.3296 3.1035 8.5622
SNU-410 CTRP2 8.2788 20.8601 0.4062 17.8877
HPAF-II CTRP2 8.5409 14.7844 3.5386 6.5366
KP-2 CTRP2 8.584 18.3843 1.8415 12.7502
HPAC CTRP2 8.6637 17.786 2.1872 11.4076
Capan-2 CTRP2 8.9325 14.4161 3.9502 4.5322
PaTu 8988s CTRP2 9.8515 20.5264 1.6776 11.5105
PK-59 CTRP2 10.5082 31.0923 -2.9823 22.7905
PaTu 8902 CTRP2 13.9102 31.7269 -0.9835 14.2387
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 8.6251 21.207 0.4915 17.0792
Hs 944.T CTRP2 -6.9672 7.7711 -8.6621 67.8748
WM266-4 CTRP2 -3.402 -0.6954 -3.4031 62.8478
A-375 CTRP2 -2.6051 4.9817 -3.1276 56.0462
IGR-37 CTRP2 -1.9068 1.7054 -1.9326 52.9098
Hs 294T CTRP2 -1.1076 2.5248 -1.2446 40.2259
RPMI-7951 CTRP2 -0.5013 7.797 -1.6444 45.1606
Hs 852.T CTRP2 -0.4058 7.0592 -1.2961 44.3789
LOX-IMVI CTRP2 0.1741 5.4971 -0.2213 40.1129
G-361 CTRP2 0.4339 9.7159 -1.3625 41.1057
WM793 CTRP2 0.5615 26.779 -9.1843 45.9063
MeWo CTRP2 0.7147 29.3343 -10.294 45.9451
A101D CTRP2 0.8171 5.3263 0.1172 27.8293
WM88 CTRP2 0.8217 25.14 -8.1418 45.0489
WT2-iPS CTRP2 0.8256 27.1805 -10.2786 43.3963
IGR-39 CTRP2 1.2178 4.3976 0.8659 23.4044
A2058 CTRP2 2.1376 8.6875 0.0126 23.9543
COLO 800 CTRP2 2.212 11.1154 -0.1172 32.7314
SK-MEL-24 CTRP2 2.9492 8.9982 1.571 25.5397
CJM [Human melanoma] CTRP2 3.0055 6.1479 2.6991 21.3186
WM115 CTRP2 3.0065 12.9593 -0.1845 30.6287
COLO 829 CTRP2 3.5029 20.8444 -3.5674 35.7413
K029AX CTRP2 3.5487 6.1119 3.3021 17.4912
COLO 792 CTRP2 3.5723 13.027 -0.8186 23.1401
IGR-1 CTRP2 3.9689 14.7967 -0.1624 28.0961
SK-MEL-5 CTRP2 4.475 10.9546 2.184 19.3283
HT-144 CTRP2 4.7161 11.8638 0.71 14.6136
SK-MEL-1 CTRP2 4.7918 10.0811 2.9063 15.7726
Mel JuSo CTRP2 4.8328 21.283 -2.6067 31.4405
UACC-257 CTRP2 5.0545 13.4175 1.5035 20.4582
UACC-62 CTRP2 5.1005 12.2359 2.1307 18.0855
Mel Ho CTRP2 5.7068 14.4785 1.5428 18.9179
WM1799 CTRP2 6.4153 20.7209 -0.9871 24.9431
Hs 895.T CTRP2 6.7352 12.7645 3.2413 10.4551
Hs 940.T CTRP2 6.9284 12.104 3.7161 8.1888
SK-MEL-28 CTRP2 7.0102 7.7736 5.7929 0.1394
SK-MEL-3 CTRP2 7.091 15.6546 2.0812 14.3263
Hs 934.T CTRP2 7.3625 8.9538 5.486 0.7245
MDA-MB-435S CTRP2 7.5861 15.7978 2.3853 12.3534
SK-MEL-31 CTRP2 7.7799 16.0375 2.4101 11.9461
SK-MEL-30 CTRP2 7.9111 15.8178 2.6125 10.9775
Hs 688(A).T CTRP2 7.92 14.4291 3.2936 8.339
HMCB CTRP2 8.1217 16.5461 0.8129 8.458
Hs 839.T CTRP2 8.2214 13.4351 3.9675 5.3025
WM983B CTRP2 8.2625 25.482 -1.8934 23.827
IPC-298 CTRP2 8.2783 37.9607 -8.0924 33.1006
RVH-421 CTRP2 9.4957 17.8949 2.6892 8.4646
Hs 936.T CTRP2 11.2065 34.0812 -3.9394 23.6566
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 1.0095 8.2936 -0.9213 30.8145
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CHP-212 CTRP2 -4.1348 0.1362 -4.1553 66.8477
SiMa CTRP2 -3.2039 -0.9012 -3.2042 61.5857
KP-N-SI9s CTRP2 -2.5189 -0.8304 -2.519 57.0491
IMR-32 CTRP2 -1.6345 -0.7873 -1.6345 51.1581
NB1 CTRP2 -0.6107 0.0941 -0.6107 44.3373
CHP-126 CTRP2 0.4082 4.1802 0.284 37.922
SK-N-BE(2) CTRP2 2.0815 9.6791 0.3798 31.8353
Kelly CTRP2 2.1994 6.2005 1.8046 26.9761
SK-N-AS CTRP2 3.3822 9.5532 1.7705 23.6353
SK-N-SH CTRP2 4.0966 8.1719 2.0529 9.8014
SK-N-FI CTRP2 4.6284 12.4627 1.5903 21.1284
MHH-NB-11 CTRP2 4.8847 11.2508 2.4212 17.4652
SK-N-DZ CTRP2 7.1906 15.0023 2.4811 12.6556
NH-6 CTRP2 8.048 9.7599 5.4752 0.3821
KP-N-YN CTRP2 8.8132 10.6912 5.4354 0.2188
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1196 CTRP2 -0.3452 15.593 -4.7242 46.4707
SNU-478 CTRP2 0.1068 4.3632 -0.0659 40.0264
SNU-1079 CTRP2 0.4436 5.7736 0.0038 38.5139
HuCC-T1 CTRP2 1.8858 7.9344 0.8791 31.0107
SNU-869 CTRP2 2.7792 11.3357 0.3526 29.8349
HuH-28 CTRP2 4.6258 10.1457 2.7179 16.9105
SNU-308 CTRP2 5.7977 15.2103 1.2542 19.7209
SNU-245 CTRP2 5.8847 11.3734 3.2456 12.0326
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U2OS CTRP2 -5.2049 7.5563 -6.6761 63.8691
SK-N-MC CTRP2 -4.4452 -2.3152 -4.4453 69.8229
MHH-ES-1 CTRP2 -2.7765 -1.1638 -2.7765 58.7648
SK-ES-1 CTRP2 -2.4809 -0.5476 -2.481 56.7933
A-673 CTRP2 -1.3981 -0.6903 -1.3981 49.5832
TC71 CTRP2 -1.268 0.0187 -1.268 48.7165
SaOS-2 CTRP2 0.0012 8.2914 -1.2767 42.6437
HOS CTRP2 2.0898 5.9499 1.2191 19.0232
MG-63 CTRP2 3.0169 12.9445 -0.1674 30.5572
SJSA-1 CTRP2 4.3671 14.608 0.2954 25.8819
G-292 clone A141B1 CTRP2 4.3852 15.2384 0.0008 26.6641
CAL-78 CTRP2 5.0182 11.5086 2.4161 17.1823
Hs 888.T CTRP2 6.5873 12.0335 3.4894 9.7055
Hs 822.T CTRP2 6.7675 7.9722 5.5956 0.8656
SW1353 CTRP2 7.2778 14.489 2.8007 11.2764
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 72 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-157 CTRP2 -3.908 2.8792 -4.1451 63.4518
DU4475 CTRP2 -2.6907 -0.3716 -2.6912 58.1779
CAL-148 CTRP2 -1.8533 0.5282 -1.8548 52.6103
CAL-51 CTRP2 -1.5513 0.6411 -1.5523 50.6029
SK-BR-3 CTRP2 -1.2947 8.6324 -2.7957 49.2474
CAL-85-1 CTRP2 -0.5969 6.1986 -1.7242 39.0637
BT-549 CTRP2 0.2206 10.8642 -2.0593 42.7654
MDA-MB-468 CTRP2 0.2577 3.0748 0.2299 38.6383
HCC38 CTRP2 0.5746 5.5774 0.1957 37.5271
AU565 CTRP2 1.7805 8.4559 0.566 32.2736
HCC1806 CTRP2 2.8723 10.8828 0.6536 28.7044
HMC-1-8 CTRP2 3.3958 12.8653 0.2359 28.4729
MCF-7 CTRP2 4.5616 10.3296 2.5682 17.6494
HCC2218 CTRP2 4.9458 23.5159 -3.6229 32.8789
BT-20 CTRP2 5.5897 9.4798 3.9344 9.7843
HCC1954 CTRP2 5.8369 18.7383 -0.4763 24.7878
Hs 578Bst CTRP2 5.9972 11.2229 3.4157 11.1114
MDA-MB-231 CTRP2 6.0689 15.0228 1.5756 18.0664
HCC1500 CTRP2 6.4319 24.3314 -2.7782 28.7084
EFM-192A CTRP2 7.0104 19.2675 0.2197 20.6198
KPL-1 CTRP2 7.1269 8.4785 5.5672 0.6507
MDA-MB-415 CTRP2 7.1864 8.8872 5.4241 1.062
CAL-120 CTRP2 7.4019 9.2117 5.3978 0.9656
Hs 578T CTRP2 7.5539 10.1699 5.0624 1.967
HCC1395 CTRP2 7.558 13.8937 3.2985 8.8654
HCC1143 CTRP2 7.6203 16.9297 1.8527 14.2438
ZR-75-1 CTRP2 7.8287 16.0456 2.4417 11.75
HCC1428 CTRP2 7.8498 10.8236 4.9388 2.1085
HDQ-P1 CTRP2 7.9015 13.0275 3.9528 5.7758
HCC1419 CTRP2 7.9016 9.843 5.3796 0.6787
MDA-MB-453 CTRP2 8.1042 19.6709 0.8623 16.7711
JIMT-1 CTRP2 8.1719 13.5712 3.872 5.7336
BT-474 CTRP2 8.3083 9.7953 5.5635 0.1562
ZR-75-30 CTRP2 8.3647 10.2091 5.4365 0.3418
HCC202 CTRP2 8.3738 10.4425 5.353 0.5073
MDA-MB-361 CTRP2 8.4632 10.1144 5.5086 0.1964
T-47D CTRP2 8.4986 14.0077 3.8748 5.3126
HCC1937 CTRP2 8.5556 10.9247 5.2458 0.6676
CAMA-1 CTRP2 8.9098 18.7803 1.8774 12.1422
BT 145 CTRP2 -4.3745 -2.5996 -4.3745 69.3936
BT 239 CTRP2 -3.0519 -0.2914 -3.0537 60.5317
BT164 CTRP2 -2.3593 0.5332 -2.3638 55.9439
BT 112 CTRP2 -1.2277 1.1726 -1.2306 48.4513
BT 330 CTRP2 -0.0347 6.2309 -0.6418 41.818
BT 428 CTRP2 -0.0203 2.773 -0.0417 40.4678
BT 228 CTRP2 0.5154 4.0988 0.409 37.1629
BT 286 CTRP2 0.6144 10.4316 -1.4667 40.6098
BT 131 CTRP2 0.9584 9.4915 -0.7181 38.1311
BT 416 CTRP2 1.4793 3.3402 1.4716 30.4391
BT 498 CTRP2 2.2015 10.6355 0.0867 32.2473
BT 245 CTRP2 2.8386 10.434 0.8238 28.2883
BT 340 CTRP2 2.9366 12.7971 -0.1755 30.7969
BT 248 CTRP2 3.0126 11.1339 0.6781 28.2374
BT 232 CTRP2 3.0902 12.4517 0.1375 29.5601
BT 504 CTRP2 3.2178 11.2046 0.8485 27.1539
BT 440 CTRP2 4.0428 12.1376 1.2028 23.8666
BT 482 CTRP2 4.3062 12.423 1.3116 22.8557
BT 333 CTRP2 4.638 15.5294 0.0843 25.8485
BT147 CTRP2 5.0643 17.3069 -0.4231 26.2599
BT 172 CTRP2 6.4514 16.9453 0.9293 19.491
BT 216 CTRP2 7.2944 17.3415 1.4008 16.3778
BT 139 CTRP2 7.5526 16.0061 2.2578 12.8842
BT 422 CTRP2 7.6793 9.0059 5.6061 0.2597
BT 187 CTRP2 7.798 15.7594 2.5595 11.3556
BT 231 CTRP2 8.4214 10.8214 5.227 0.7822
BT 320 CTRP2 8.7783 17.4232 2.4406 10.3263
BT 224 CTRP2 8.8244 16.1064 3.0988 7.8287
BT 359 CTRP2 8.9788 18.1245 2.2403 10.765
BT 179 CTRP2 9.1266 14.7137 3.9292 4.399
BT 159 CTRP2 9.4444 16.8782 3.1307 6.9333
BT 328 CTRP2 9.5908 19.7656 1.8667 11.2232
BT 444 CTRP2 9.8036 21.5642 1.1497 13.2959
⏷ Show the Full List of 72 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 2.166 8.7436 0.8588 30.1861
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med CTRP2 -5.0714 -3.881 -5.0714 74.0525
AM-38 CTRP2 -2.8269 -0.4599 -2.8274 59.0795
SF295 CTRP2 -1.3687 2.424 -1.4151 49.4027
SF268 CTRP2 -1.2931 2.4585 -1.3389 48.9106
42-MG-BA CTRP2 -0.3431 1.9193 -0.3472 42.5664
LN-18 CTRP2 -0.2159 5.087 -0.5521 42.4432
Daoy CTRP2 0.1633 3.4129 0.1088 39.3435
SF539 CTRP2 0.7302 3.0274 0.7173 35.4461
U-118MG CTRP2 1.0726 6.9019 0.3622 35.2497
SF126 CTRP2 1.3463 7.1522 0.577 33.6961
KNS-60 CTRP2 1.3877 5.332 0.9716 27.6311
8-MG-BA CTRP2 1.6069 4.2354 1.3386 20.0875
GOS-3 CTRP2 2.0958 4.5973 1.756 16.6557
GMS-10 CTRP2 2.4919 7.2207 1.0515 18.5673
DBTRG-05MG CTRP2 2.5999 10.7727 0.4296 30.1352
SNU-626 CTRP2 2.8488 5.565 2.6751 21.8879
DK-MG CTRP2 2.856 8.804 1.5569 25.8558
SW1088 CTRP2 3.1186 9.5665 1.4966 25.3165
U-251MG CTRP2 3.3506 12.2847 0.4694 27.9305
GB-1 CTRP2 3.493 7.8269 2.6303 20.1595
SNU-466 CTRP2 3.9814 7.0441 3.4585 15.6475
SNU-738 CTRP2 3.9971 11.2418 1.5904 22.6611
Becker CTRP2 4.0234 9.6853 2.352 19.8085
A-172 CTRP2 4.0361 8.4123 2.9448 17.4875
Hs 683 CTRP2 4.0815 8.3863 3.0027 17.1425
ONS-76 CTRP2 4.1523 7.7722 3.3432 15.6245
M059K CTRP2 4.5179 12.1955 0.3863 16.3983
SNB-75 CTRP2 4.5976 10.3236 2.6053 17.4188
YH-13 CTRP2 4.7371 8.642 2.3263 7.1689
TM-31 CTRP2 4.9533 9.806 1.9138 8.7033
NMC-G1 CTRP2 5.4101 11.0355 3.0023 14.0044
KALS-1 CTRP2 5.4653 13.1015 2.0224 17.6965
GaMG CTRP2 6.41 15.2081 1.7635 16.7336
SW1783 CTRP2 6.6588 14.6734 2.2306 14.5508
SNU-489 CTRP2 6.8703 13.0124 3.2224 10.2958
KG-1-C CTRP2 7.051 9.8403 4.9055 3.1573
KNS-81 CTRP2 7.0906 11.6586 4.0542 6.5433
CAS-1 CTRP2 7.093 15.644 2.0881 14.2976
SNU-201 CTRP2 7.4023 10.0883 5.0107 2.3182
CCF-STTG1 CTRP2 7.4517 12.3834 3.9572 6.3904
SNU-1105 CTRP2 7.599 8.7001 5.6859 0.1468
U-87MG ATCC CTRP2 7.7723 16.6648 2.0964 13.1153
YKG-1 CTRP2 7.7937 13.0812 3.8554 6.3068
LN-229 CTRP2 8.2235 17.889 1.8253 13.3621
T98G CTRP2 8.4258 17.0802 2.3631 11.1219
KNS-42 CTRP2 8.598 14.7965 3.5694 6.3465
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP2 -4.0249 -1.4982 -4.0253 66.9808
JHUEM-3 CTRP2 -1.4524 8.4716 -2.9082 49.9623
MFE-296 CTRP2 -0.8028 4.0583 -0.9946 45.9062
ESS-1 CTRP2 0.9049 2.6934 0.8729 24.5054
HEC-6 CTRP2 1.1844 7.3287 0.3416 34.9085
JHUEM-1 CTRP2 2.4535 7.5722 1.6232 26.8188
KLE CTRP2 2.5865 11.589 0.0439 31.2189
HEC-265 CTRP2 2.6551 8.599 1.4325 26.8648
JHUEM-7 CTRP2 2.6741 9.6695 0.9962 28.2294
HEC-151 CTRP2 2.9039 12.195 0.0763 30.2359
RL95-2 CTRP2 3.0735 9.8253 1.3353 25.9876
HEC-50B CTRP2 3.1936 15.7267 -1.3382 32.7506
HEC-59 CTRP2 4.3363 13.1324 0.9926 23.8341
MFE-319 CTRP2 6.1194 11.6458 1.838 7.0559
AN3-CA CTRP2 6.6528 14.7348 2.1953 14.6942
HEC-251 CTRP2 7.6529 18.2905 1.2048 16.4162
HEC-1-B CTRP2 7.8331 15.8325 2.5491 11.3394
HEC-1-A CTRP2 8.1478 12.8832 4.1785 4.5863
HEC-108 CTRP2 8.8355 17.3359 2.5212 9.952
EN CTRP2 9.204 17.8966 2.4995 9.5263
EFE-184 CTRP2 10.2358 19.6653 2.3294 8.8134
Ishikawa (Heraklio) 02 ER- CTRP2 7.7214 12.3537 4.154 5.2272
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TUHR4TKB CTRP2 -0.2748 7.4211 -1.2716 43.7809
786-O CTRP2 0.8676 4.7056 0.696 35.0324
UO-31 CTRP2 1.0435 14.0933 -2.6476 40.7629
CAL-54 CTRP2 1.6561 7.0265 0.9551 31.5277
ACHN CTRP2 1.9274 6.6096 1.3852 29.2634
KMRC-1 CTRP2 2.2026 12.7153 -0.8582 34.4465
769-P CTRP2 3.351 11.2289 0.9684 26.4182
BFTC-909 CTRP2 4.4026 15.1216 0.0741 26.4218
A-498 CTRP2 4.9242 10.7957 1.4026 11.1216
TUHR14TKB CTRP2 4.9366 10.5721 2.802 15.8541
RCC10RGB CTRP2 5.1962 13.8479 1.415 20.451
VMRC-RCZ CTRP2 5.4059 11.6689 1.3315 10.524
Caki-1 CTRP2 5.7082 11.2514 1.7497 8.1112
Caki-2 CTRP2 6.1209 11.1502 2.0728 6.0173
KMRC-20 CTRP2 6.1421 13.0867 2.6043 14.0964
TUHR10TKB CTRP2 7.3718 12.8331 3.6826 7.6166
VMRC-RCW CTRP2 7.5325 12.8678 3.7792 6.9855
KMRC-2 CTRP2 7.5902 17.1482 1.7222 14.7562
OS-RC-2 CTRP2 7.8456 14.5453 3.1854 8.8724
SNU-1272 CTRP2 10.7573 22.9952 1.1013 12.1875
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CL-34 CTRP2 -7.9472 5.0208 -8.9582 72.7179
SK-CO-1 CTRP2 -3.0793 0.6841 -3.0958 60.4771
SW48 CTRP2 -1.5926 2.7838 -1.6769 50.8392
LS513 CTRP2 -1.558 2.2935 -1.6032 50.6306
CW-2 CTRP2 -1.0056 11.4493 -3.5864 48.2432
LoVo CTRP2 -0.7387 15.8575 -5.24 47.7906
SNU-C1 CTRP2 -0.6305 2.1359 -0.643 44.4995
MDST8 CTRP2 -0.0888 7.2253 -1.005 42.6317
SNU-175 CTRP2 0.1795 8.1982 -1.0509 41.6081
RKO CTRP2 0.2189 14.4352 -3.6301 44.1753
GP2d CTRP2 0.3538 9.5196 -1.3687 41.4101
SNU-407 CTRP2 0.5598 4.9762 0.3131 37.2696
SNU-C5 CTRP2 0.5808 10.5879 -1.5672 40.8725
LS180 CTRP2 0.9047 9.9951 -0.981 38.8064
SNU-81 CTRP2 1.0043 90.1933 -40.3006 48.4866
CCK-81 CTRP2 1.006 11.4006 -1.4748 39.2875
NCI-H508 CTRP2 1.3498 6.7017 0.7276 33.2475
SNU-C2A CTRP2 1.5169 8.5875 0.2342 34.0491
HT115 CTRP2 1.92 11.7207 -0.6853 34.9232
CL-11 CTRP2 2.1628 11.4251 -0.3066 33.3372
SNU-61 CTRP2 2.9054 12.0782 0.1326 30.0815
COLO 320 CTRP2 3.3973 16.7364 -1.6412 32.8452
KM12 CTRP2 3.8462 16.0595 -0.8954 30.1885
RCM-1 [Human ESC] CTRP2 4.3449 11.8163 1.6434 21.616
LS1034 CTRP2 5.097 15.1724 0.6687 23.1033
T84 CTRP2 5.2819 10.1815 3.3105 13.0283
COLO 678 CTRP2 5.5428 17.2909 -0.0021 24.114
C2BBe1 CTRP2 5.7105 14.2911 1.6396 18.5695
COLO201 CTRP2 5.9994 13.1024 2.4779 14.8692
HCT 15 CTRP2 6.1003 13.711 2.2576 15.5137
SW1417 CTRP2 6.1904 13.0092 2.6829 13.6943
SW620 CTRP2 6.2231 19.2925 -0.4313 23.9075
HT-55 CTRP2 6.5465 16.0501 1.4536 17.562
SW948 CTRP2 6.6526 12.8701 3.1242 11.0744
HCT 8 CTRP2 6.6867 19.8374 -0.3245 22.7414
HCT 116 CTRP2 7.1205 10.6848 4.5483 4.4895
DLD-1 CTRP2 7.183 11.6174 4.1403 6.0505
HCC-56 CTRP2 7.2784 15.0713 2.5136 12.3821
SW1116 CTRP2 7.4558 10.3481 4.924 2.5814
HT-29 CTRP2 7.555 8.6791 5.6766 0.1735
COLO205 CTRP2 7.6101 16.939 1.8406 14.3043
NCI-H716 CTRP2 7.6161 14.7623 2.9158 10.278
LS411N CTRP2 7.682 12.6327 3.9948 5.9104
NCI-H747 CTRP2 7.9639 14.2468 3.4117 7.8129
OUMS-23 CTRP2 7.9658 8.9994 5.7144 0.0523
SNU-503 CTRP2 8.5598 20.4733 0.8038 16.224
SNU-C4 CTRP2 10.105 21.0395 1.6008 11.43
⏷ Show the Full List of 47 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HLF CTRP2 -2.4186 1.7136 -2.5333 49.8518
Li-7 CTRP2 0.1442 4.8334 -0.109 39.9788
JHH-5 CTRP2 0.5179 5.8645 0.0614 38.0846
HuH-1 CTRP2 0.5928 6.1383 -0.432 30.6604
JHH-4 CTRP2 2.3327 8.9493 0.9494 29.3948
PLC/PRF/5 CTRP2 3.0088 7.4292 1.4502 15.3223
SNU-398 CTRP2 4.083 9.7926 2.3607 19.6244
JHH-6 CTRP2 5.1323 5.9897 3.8038 0.1988
SNU-475 CTRP2 5.2719 10.468 1.8224 8.5388
JHH-2 CTRP2 5.4413 7.9527 3.1325 2.3372
SNU-423 CTRP2 5.4566 15.408 0.8641 21.7121
JHH-1 CTRP2 6.2774 14.059 0.7877 11.3304
SNU-182 CTRP2 6.4217 11.7169 3.5161 9.894
SNU-761 CTRP2 6.5092 14.5361 1.4571 12.9926
SNU-387 CTRP2 6.7005 17.8111 0.6985 19.749
SNU-878 CTRP2 6.9157 16.4275 1.5599 16.5074
SNU-449 CTRP2 7.3264 17.0508 1.5697 15.7417
HuH-6 CTRP2 7.485 9.9365 5.1274 1.8053
Hep 3B2.1-7 CTRP2 7.8188 16.3529 2.2838 12.3531
Hep-G2 CTRP2 8.0058 19.7336 0.7577 17.2621
SK-HEP-1 CTRP2 8.8438 17.6565 2.3731 10.4785
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 143 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 668 CTRP2 -4.7561 -2.0048 -4.7565 71.6714
NCI-H2286 CTRP2 -4.5604 5.2513 -5.3224 63.8695
Lu-99 CTRP2 -3.7601 -2.4612 -3.7601 65.3186
NCI-H1339 CTRP2 -3.498 0.4808 -3.5521 57.6591
NCI-H1734 CTRP2 -3.3547 -1.4549 -3.3547 62.6095
HCC78 CTRP2 -3.2927 -1.5052 -3.2927 62.2002
NCI-H526 CTRP2 -3.0742 -2.1817 -3.0742 60.7491
DV-90 CTRP2 -2.8806 1.2078 -2.911 59.099
NCI-H1155 CTRP2 -2.4958 -0.2977 -2.4962 56.8869
EBC-1 CTRP2 -2.2474 2.2093 -2.3144 54.9827
NCI-H1184 CTRP2 -2.2389 2.9748 -2.3793 54.7569
NCI-H1105 CTRP2 -2.0964 4.0062 -2.6391 47.832
NCI-H23 CTRP2 -1.9437 1.8366 -1.9765 53.1357
NCI-H211 CTRP2 -1.8911 4.1677 -2.1851 52.5122
NCI-H1703 CTRP2 -1.7643 4.9089 -2.1964 51.7069
NCI-H1341 CTRP2 -1.6526 1.7439 -1.6738 51.259
SK-MES-1 CTRP2 -1.6384 3.1798 -1.7666 51.1093
NCI-H2110 CTRP2 -1.3236 -0.0356 -1.3236 49.0865
COR-L279 CTRP2 -1.1129 3.2486 -1.2179 47.7865
NCI-H1623 CTRP2 -0.9494 2.909 -1.0136 46.6884
HCC1438 CTRP2 -0.8632 1.4638 -0.8663 46.0265
NCI-H1694 CTRP2 -0.7799 3.9363 -0.9514 45.7351
NCI-H2023 CTRP2 -0.7568 8.4752 -2.1595 46.6607
NCI-H292 CTRP2 -0.6378 5.3676 -1.0751 45.1876
HCC1588 CTRP2 -0.4737 5.9179 -1.0349 44.3652
NCI-H2087 CTRP2 -0.4579 6.5415 -1.1934 44.4904
NCI-H1568 CTRP2 -0.2172 2.5395 -0.2342 41.7648
COR-L95 CTRP2 -0.1313 11.0376 -2.4997 44.4567
NCI-H1975 CTRP2 0.0918 2.7671 0.0736 39.7133
NCI-H1666 CTRP2 0.3917 19.4224 -5.789 44.9805
NCI-H2170 CTRP2 0.4082 7.3867 -0.5192 39.7853
NCI-H1650 CTRP2 0.4285 9.9215 -1.4515 41.253
HARA [Human squamous cell lung carcinoma] CTRP2 0.5038 5.2449 0.1958 37.7976
NCI-H460 CTRP2 0.5536 6.7508 -0.1547 38.4556
SK-LU-1 CTRP2 0.5716 9.3007 -1.0508 40.1161
NCI-H2405 CTRP2 0.5832 7.4288 -0.3438 38.7534
SBC-5 CTRP2 0.6444 2.2311 0.6436 35.9782
A-549 CTRP2 0.6833 9.6022 -1.0532 39.7144
NCI-H226 CTRP2 0.7543 6.6445 -0.1547 33.6361
EPLC-272H CTRP2 0.7715 7.123 -0.037 37.3578
NCI-H2009 CTRP2 1.0349 15.3449 -3.2365 41.4329
NCI-H1435 CTRP2 1.1801 23.9768 -7.2401 43.9291
NCI-H2228 CTRP2 1.1852 9.8399 -0.6227 37.1578
DMS 53 CTRP2 1.217 4.6565 1.0799 32.6118
PC-14 CTRP2 1.2583 8.6748 -0.0751 35.7009
NCI-H2081 CTRP2 1.2923 4.4931 1.1848 32.0152
NCI-H1944 CTRP2 1.312 16.0198 -3.2817 40.7071
DMS 79 CTRP2 1.4812 6.3063 0.9906 32.0009
COR-L105 CTRP2 1.5187 5.3222 0.8713 22.3583
LCLC-97TM1 CTRP2 1.7315 13.6883 -1.7766 37.5189
RERF-LC-MS CTRP2 1.7733 6.8168 1.1516 30.5239
RERF-LC-A1 CTRP2 1.8668 12.6311 -1.1536 36.0262
NCI-H1355 CTRP2 1.8783 15.6285 -2.5458 38.2574
HCC15 CTRP2 1.996 8.4484 0.7978 30.9041
NCI-H520 CTRP2 2.0366 5.9301 1.7013 27.8463
NCI-H650 CTRP2 2.0745 11.8859 -0.6047 34.2817
NCI-H647 CTRP2 2.1002 9.9753 0.272 32.07
SW1271 CTRP2 2.1219 9.8905 0.3311 31.843
HOP-62 CTRP2 2.1432 9.2096 0.6425 30.9004
NCI-H838 CTRP2 2.7141 9.1509 1.2619 27.259
DMS 273 CTRP2 2.7616 6.0686 1.853 14.1504
NCI-H146 CTRP2 2.8596 16.0089 -1.7896 34.4635
COR-L51 CTRP2 2.8678 10.6189 0.7694 28.3708
NCI-H1395 CTRP2 2.9418 9.5668 1.3158 26.4242
Calu-3 CTRP2 2.9668 10.1158 1.0968 27.0688
NCI-H446 CTRP2 3.2537 10.718 1.11 26.2293
NCI-H2171 CTRP2 3.4122 8.0576 2.4507 21.0596
NCI-H322 CTRP2 3.5987 8.7259 1.3493 14.2797
NCI-H69 CTRP2 3.6057 6.7479 3.1624 17.8364
HCC44 CTRP2 3.7102 13.2429 0.3534 27.3277
DMS 114 CTRP2 3.8488 7.2536 3.2361 16.8661
HCC366 CTRP2 3.8897 9.798 2.1673 20.8462
NCI-H1693 CTRP2 4.0838 10.8645 1.8542 21.5048
NCI-H1373 CTRP2 4.1495 13.221 0.7761 24.9711
NCI-H1651 CTRP2 4.2036 8.2389 3.1927 16.0795
NCI-H358 CTRP2 4.4407 15.4559 -0.0566 26.6905
NCI-H441 CTRP2 4.4553 10.2137 2.5225 18.082
NCI-H522 CTRP2 4.5256 12.7333 1.3629 22.1566
LOU-NH91 CTRP2 4.7745 11.1597 2.3642 17.9376
NCI-H1092 CTRP2 4.7768 11.2258 2.334 18.0483
Lu-65 CTRP2 4.7921 8.8078 3.518 13.306
NCI-H2196 CTRP2 4.8827 8.5244 3.7402 12.1856
NCI-H2141 CTRP2 4.8941 11.2991 2.4061 17.5018
NCI-H661 CTRP2 4.9715 18.115 -0.9067 27.6566
NCI-H2029 CTRP2 5.0186 10.4459 2.9396 15.1185
NCI-H810 CTRP2 5.1372 18.1811 -0.7956 27.036
NCI-H1581 CTRP2 5.1997 12.3664 2.1546 17.7766
HCC2108 CTRP2 5.2875 13.1968 1.8193 18.8236
NCI-H196 CTRP2 5.2876 12.1193 2.3553 16.8212
NCI-H841 CTRP2 5.4665 13.4702 1.8395 18.3652
Sq-1 CTRP2 5.5452 10.0385 3.6175 11.1961
HCC827 CTRP2 5.6984 18.5551 -0.5016 25.1331
NCI-H1755 CTRP2 5.8007 10.2676 3.7264 10.2149
NCI-H1792 CTRP2 5.8042 12.0897 2.8193 13.9183
SW1573 CTRP2 5.8558 17.065 0.3761 22.3813
SHP-77 CTRP2 5.8711 14.5199 1.6614 18.1624
HCC1195 CTRP2 5.8925 14.4874 1.6956 17.9973
NCI-H1915 CTRP2 5.932 17.3069 0.3192 22.3947
COR-L88 CTRP2 6.0219 14.0868 2.0044 16.6163
LUDLU-1 CTRP2 6.0559 12.8412 2.6556 14.0641
NCI-H2444 CTRP2 6.0645 7.4546 4.5458 0.821
DMS 454 CTRP2 6.1338 11.8212 3.2301 11.6076
NCI-H1793 CTRP2 6.2247 20.4239 -0.9956 25.3261
ChaGo-K-1 CTRP2 6.3378 14.1114 2.2527 15.0706
HCC1833 CTRP2 6.443 17.6654 0.5627 20.6574
NCI-H1563 CTRP2 6.6548 12.7114 3.2049 10.7448
LK2 CTRP2 6.7606 15.5509 1.874 15.6773
HCC2279 CTRP2 6.7863 14.5725 2.3818 13.7464
NCI-H1869 CTRP2 6.847 14.5755 2.4279 13.4614
NCI-H2126 CTRP2 6.9072 10.3802 4.5467 4.8121
VMRC-LCD CTRP2 6.9148 22.0085 -1.2244 24.5905
NCI-H2291 CTRP2 6.9582 14.5036 2.5502 12.7952
BEN CTRP2 7.0046 8.8916 5.3191 1.6183
HCC95 CTRP2 7.0453 10.4101 4.6289 4.2725
NCI-H1299 CTRP2 7.1393 16.4177 1.7396 15.4747
T3M-10 CTRP2 7.14 13.2141 3.3267 9.4209
IA-LM CTRP2 7.2485 12.0216 3.9901 6.5612
NCI-H1838 CTRP2 7.2634 14.8641 2.6047 12.059
HCC2935 CTRP2 7.2885 9.4181 5.2469 1.579
NCI-H2106 CTRP2 7.2918 12.0332 4.0151 6.3942
RERF-LC-Ad1 CTRP2 7.3364 8.2133 5.76 0.1024
HCC4006 CTRP2 7.4314 10.2561 4.9515 2.5065
NCI-H1573 CTRP2 7.4383 15.1733 2.5831 11.8488
LCLC-103H CTRP2 7.5192 11.7689 4.2983 4.931
NCI-H2085 CTRP2 7.5455 13.9199 3.2768 8.971
COLO 699 CTRP2 7.6664 24.3125 -1.7756 24.5431
LC-1/sq-SF CTRP2 7.6914 12.5157 4.057 5.6508
HCC1171 CTRP2 7.7709 18.9714 0.9573 17.0231
NCI-H889 CTRP2 7.7835 11.2185 4.7229 2.96
NCI-H2172 CTRP2 7.8903 15.5275 2.7393 10.5284
HOP-92 CTRP2 8.0569 21.0496 0.1459 19.016
NCI-H727 CTRP2 8.3967 17.4977 2.14 11.9755
EKVX CTRP2 8.4426 17.0937 2.3682 11.078
NCI-H2030 CTRP2 8.503 16.3588 2.7644 9.5224
MOR/CPR CTRP2 8.5548 18.0663 1.9753 12.3239
RERF-LC-Ad2 CTRP2 8.6053 21.6588 0.255 17.8118
NCI-H2342 CTRP2 8.7917 16.7838 2.7556 9.1507
Calu-1 CTRP2 9.1255 19.9418 1.4658 13.2283
CAL-12T CTRP2 9.1722 17.6136 2.6127 9.1596
NCI-H2122 CTRP2 9.6811 25.7238 -0.9537 19.4521
KNS-62 CTRP2 11.0162 24.7224 0.4529 13.8057
Calu-6 CTRP2 11.418 28.0281 -0.8558 16.838
Hs 888.Lu CTRP2 4.2087 11.1683 1.8282 21.2884
⏷ Show the Full List of 143 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 -3.31 1.5467 -3.3732 61.4345
Yamato-SS CTRP2 0.4282 12.1659 -2.4032 42.4251
Rh41 CTRP2 -4.3566 11.9569 -7.3311 58.9093
TTC-709 CTRP2 -2.8825 2.1895 -2.9771 58.7255
G-402 CTRP2 -2.2975 1.2413 -2.3575 48.9515
Hs 729.T CTRP2 -1.9948 7.6307 -3.2083 52.4694
KYM-1 CTRP2 -1.3518 1.9098 -1.372 49.2835
TE 617.T CTRP2 -1.3296 -0.2483 -1.3296 49.1263
A-204 CTRP2 -1.2457 4.857 -1.6216 48.7477
BT-16 CTRP2 -1.1123 0.3177 -1.1123 47.6791
TE 441.T CTRP2 -0.6126 2.7733 -0.7521 36.5013
SW982 CTRP2 -0.5174 8.1993 -1.8024 45.3724
G-401 CTRP2 -0.3753 2.0334 -0.3815 42.7867
HT-1080 CTRP2 -0.1344 57.9836 -25.2385 48.755
GCT CTRP2 0.3225 5.247 -0.0018 39.0043
Tm87-16 CTRP2 0.7811 7.8619 -0.2815 37.8762
BT-12 CTRP2 0.9058 9.2391 -0.6721 38.2278
SK-UT-1 CTRP2 2.0355 10.1066 0.1484 32.5973
SK-LMS-1 CTRP2 2.8557 7.5507 1.2463 16.671
RD CTRP2 5.6501 15.315 1.0766 20.6174
MES-SA CTRP2 5.9009 7.4695 3.565 0.4151
RKN CTRP2 6.7387 11.411 3.9155 7.6859
Rh18 CTRP2 6.8239 13.2939 3.047 11.081
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 -3.0077 0.5049 -3.0188 60.0903
P-STS CTRP2 0.2516 4.9398 -0.0137 39.3157
H-STS CTRP2 0.699 1.3966 0.699 35.612
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 -2.358 1.5768 -2.3905 55.7923
HEY A8 CTRP2 -9.5668 19.2535 -15.7999 64.6147
A2780 CTRP2 -3.9623 1.1666 -4.0256 65.1541
OVK18 CTRP2 -3.7225 4.0892 -4.1514 61.6595
JHOC-5 CTRP2 -2.9412 -1.13 -2.9412 59.8597
Caov-3 CTRP2 -2.208 5.507 -2.8208 53.9223
OC 314 CTRP2 -1.4689 -0.9078 -1.4689 50.0546
COV434 CTRP2 -0.8834 0.8951 -0.8837 46.1548
TOV-112D CTRP2 -0.8796 2.3327 -0.905 46.1753
OAW42 CTRP2 -0.3405 2.3468 -0.4043 34.1619
TYK-nu CTRP2 -0.2528 8.7827 -1.7308 44.2069
OVTOKO CTRP2 0.311 5.5819 -0.0927 39.2672
OV7 CTRP2 0.683 5.7344 -0.179 29.4282
MCAS CTRP2 2.0624 11.3027 -0.3529 33.7493
OVCAR-8 CTRP2 2.5731 22.8832 -5.418 39.7903
TOV-21G CTRP2 2.5842 7.4116 1.0515 18.304
EFO-21 CTRP2 2.5964 13.0879 -0.6447 32.8592
OVISE CTRP2 3.1728 8.2266 2.1296 22.9185
IGROV-1 CTRP2 3.2214 11.3639 0.7777 27.3612
SK-OV-3 CTRP2 3.7433 15.5183 -0.7246 30.0431
OV56 CTRP2 4.1014 6.1986 3.0435 5.0151
DOV13 CTRP2 4.6103 8.9903 3.2546 14.8091
ES2 CTRP2 5.002 15.5122 0.416 24.0764
OAW28 CTRP2 5.9422 10.2292 3.8662 9.3487
COV362 CTRP2 6.334 17.5608 0.5257 20.981
JHOS-2 CTRP2 6.4623 14.1219 2.3484 14.4713
OV-90 CTRP2 6.6059 14.1178 2.4656 13.7554
OVCAR-5 CTRP2 6.9402 14.0576 2.7577 12.0216
COV644 CTRP2 6.9765 13.0191 3.3001 9.8011
SNU-119 CTRP2 7.1633 10.0324 4.8879 3.0781
RMG-I CTRP2 7.3961 16.7593 1.7676 14.9271
FU-OV-1 CTRP2 8.0126 10.0963 5.3293 0.747
Kuramochi CTRP2 8.1121 11.6579 4.716 2.6343
JHOM-1 CTRP2 8.2263 9.7697 5.5419 0.205
OVCAR-4 CTRP2 8.3252 13.0153 4.2265 4.1948
EFO-27 CTRP2 8.9467 16.7466 2.8757 8.4967
SNU-8 CTRP2 9.5155 19.9971 1.7058 11.8713
SNU-840 CTRP2 9.6192 19.0578 2.2213 9.9623
OVSAHO CTRP2 9.7765 20.6312 1.5778 11.9426
ONCO-DG-1 CTRP2 10.2048 21.6803 1.3625 12.0742
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 5.9667 11.7824 3.1103 12.4212
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H CTRP2 -4.4635 5.3194 -5.2336 63.4782
NCI-H28 CTRP2 -3.0408 -0.6517 -3.0413 60.4977
NCI-H2052 CTRP2 -0.1926 9.5454 -1.9589 44.1973
IST-Mes1 CTRP2 1.6329 5.8569 0.7807 22.3678
NCI-H2452 CTRP2 3.6755 10.055 1.3234 19.5557
MPP 89 CTRP2 6.5305 16.4292 1.2513 18.2808
ACC-MESO-1 CTRP2 7.3876 11.0499 4.5531 4.0999
JL-1 CTRP2 7.7763 11.1655 4.7427 2.8944
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC CTRP2 -0.268 3.0787 -0.3155 42.1801
22Rv1 CTRP2 0.6554 3.4769 0.6173 36.0256
DU145 CTRP2 2.5452 8.1584 1.4952 26.98
VCaP CTRP2 8.0253 20.2851 0.5 18.0221
PaCa-3 CTRP2 8.2175 16.3263 2.5826 10.6212
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 -2.356 -1.4131 -2.356 55.9647
A-253 CTRP2 6.6901 8.4308 3.5236 0.223
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-N87 CTRP2 -3.7456 7.7809 -5.1598 59.2553
NUGC-3 CTRP2 -3.023 -0.3066 -3.0246 60.3464
SNU-1 CTRP2 -2.5338 3.2734 -2.732 56.3413
GSS CTRP2 -1.5601 -0.0452 -1.5601 50.6621
23132/87 CTRP2 -1.1911 4.293 -1.4519 48.3733
ECC12 CTRP2 -0.713 0.4694 -0.713 45.0186
SNU-16 CTRP2 -0.1241 2.9146 -0.1557 41.186
SNU-601 CTRP2 0.5395 4.5062 0.376 37.1695
SNU-5 CTRP2 0.8423 3.0076 0.8323 34.6904
NCC-StC-K140 CTRP2 1.0067 5.6443 0.6505 34.6741
SNU-620 CTRP2 1.2512 4.2417 1.1731 32.1917
HGC-27 CTRP2 1.262 6.5076 0.6918 33.6558
NUGC-4 CTRP2 1.3606 7.9447 0.3119 34.3751
GSU CTRP2 1.6305 6.1939 1.1858 30.8825
SNU-719 CTRP2 3.7083 18.8051 -2.374 33.4503
Hs 746.T CTRP2 3.9105 12.9748 -0.5045 21.2273
ECC10 CTRP2 4.3721 22.8476 -3.7885 34.2441
LMSU CTRP2 4.6779 17.4802 -0.8487 28.1601
SNU-668 CTRP2 4.8292 13.4712 1.2752 21.7484
MKN74 CTRP2 5.038 14.8638 0.7703 22.9181
IM95 CTRP2 6.0721 15.9531 1.1131 19.635
MKN7 CTRP2 6.8804 13.0303 3.2213 10.2827
SNU-216 CTRP2 7.3359 12.6471 3.7477 7.409
HuG1-N CTRP2 7.4812 11.7753 4.2698 5.0963
AGS CTRP2 7.5012 15.1555 2.6385 11.5335
KATO III CTRP2 7.5167 12.3045 4.0401 5.9638
MKN45 CTRP2 7.5591 8.5542 5.7225 0.1046
SH-10-TC CTRP2 7.5668 11.7247 4.3507 4.659
MKN1 CTRP2 7.8551 16.3044 2.334 12.109
Fu97 CTRP2 7.8961 12.1439 4.365 4.1811
KE-39 CTRP2 8.1897 16.391 2.5316 10.8537
SNU-685 CTRP2 1.9336 10.2566 -0.0217 33.3495
SNG-M CTRP2 5.0683 24.0712 -3.7948 32.9028
SNU-1077 CTRP2 7.7385 10.6474 4.9544 2.1643
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CGTH-W-1 CTRP2 -1.6627 0.7261 -1.6646 51.3433
ML-1 [Human leukemia] CTRP2 -1.4708 4.4211 -1.7779 50.0598
FTC-133 CTRP2 0.2701 2.9313 0.2497 38.5333
SW579 CTRP2 0.4182 3.8878 0.3311 37.749
FTC-238 CTRP2 0.471 2.7271 0.4121 27.9335
BHT-101 CTRP2 0.8807 7.4538 -0.0302 36.9377
TT2609-C02 CTRP2 0.9361 7.227 -0.5241 29.7613
8505C CTRP2 1.5363 5.6092 1.2363 31.0307
CAL-62 CTRP2 2.7656 7.1356 2.1184 24.138
8305C CTRP2 3.1411 12.4843 0.1716 29.3294
B-CPAP CTRP2 4.5327 13.8925 0.7989 23.9821
TT CTRP2 8.7815 17.4225 2.4431 10.3126
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BICR 22 CTRP2 -2.3919 7.3012 -3.534 54.2812
PE/CA-PJ49 CTRP2 -1.4453 4.0047 -1.6764 49.9067
HSC-3 CTRP2 -0.4528 5.2399 -0.8438 44.0026
YD-10B CTRP2 -0.3793 1.9625 -0.3844 45.9789
CAL-33 CTRP2 -0.2535 3.0108 -0.2958 42.0713
FaDu CTRP2 -0.0754 2.966 -0.1083 40.8662
PE/CA-PJ15 CTRP2 0.1235 8.8141 -1.3396 42.2455
SNU-1076 CTRP2 0.2207 5.6367 -0.2047 39.8858
HSC-4 CTRP2 0.3336 5.2931 -0.0001 38.9566
CAL-27 CTRP2 0.5573 3.4464 0.389 27.7023
BHY CTRP2 1.6101 8.4625 0.3821 33.3447
HSC-2 CTRP2 1.825 5.1726 1.2558 19.7056
PE/CA-PJ41 (clone D2) CTRP2 2.2939 9.3661 0.7338 30.1676
PE/CA-PJ34 (clone C12) CTRP2 2.8594 8.4014 1.7285 25.251
BICR 18 CTRP2 3.0881 8.561 1.9013 23.9844
BICR 6 CTRP2 3.1764 8.606 1.9743 23.4731
Detroit 562 CTRP2 3.3754 12.1734 0.5463 27.6399
SCC-25 CTRP2 3.9145 12.5148 0.899 25.1701
SNU-1066 CTRP2 4.3131 12.7364 1.165 23.3282
BICR 56 CTRP2 4.7033 13.9696 0.9152 23.2179
SNU-46 CTRP2 5.5135 14.4314 1.4007 19.816
YD-8 CTRP2 5.8211 16.4244 0.6672 21.5698
SNU-1214 CTRP2 5.9261 12.8519 2.5416 14.7677
SCC-9 CTRP2 6.6881 18.7507 -1.2059 17.9976
BICR 31 CTRP2 7.446 22.4685 -1.0308 23.1888
BICR 16 CTRP2 7.8764 9.5154 5.496 0.409
SNU-1041 CTRP2 7.9598 15.9729 2.5717 11.0557
SNU-899 CTRP2 8.0018 16.3877 2.3994 12.3984
SCC-4 CTRP2 8.0114 14.3417 3.3985 7.7963
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JMSU-1 CTRP2 -3.0301 0.2384 -3.0367 60.2961
647V CTRP2 -2.9046 -0.7014 -2.9064 53.5544
UM-UC-3 CTRP2 -2.1618 0.7051 -2.1667 54.6401
5637 CTRP2 -1.6662 3.4949 -1.8362 51.2613
253J-BV CTRP2 -0.2412 4.7461 -0.5094 42.4749
J82 CTRP2 0.3476 4.7965 0.1181 38.6041
RT-4 CTRP2 0.4157 4.3495 0.2676 37.9399
639V CTRP2 0.549 3.0709 0.53 36.6728
CAL-29 CTRP2 1.0242 9.3645 -0.5973 37.6621
T24 CTRP2 1.0284 4.3994 0.6589 24.9182
RT-112 CTRP2 2.2609 8.8956 0.8963 29.7783
SW1710 CTRP2 2.9874 8.6045 1.778 24.7091
SCaBER CTRP2 3.576 11.2623 0.0654 19.8734
BC-3C CTRP2 3.7964 10.175 0.7978 16.2861
VM-CUB-1 CTRP2 4.0951 11.3515 1.6317 22.2704
253J CTRP2 4.6242 13.111 1.2675 22.2477
TCCSUP CTRP2 5.2969 13.57 1.6418 19.4393
KMBC-2 CTRP2 5.3666 12.8659 2.0535 17.7922
BFTC-905 CTRP2 6.2159 13.6455 2.3858 14.799
U-BLC1 CTRP2 6.8218 25.2984 -2.9427 28.3273
HT-1376 CTRP2 7.7759 13.0287 3.8686 6.2798
UM-UC-1 CTRP2 9.226 17.1894 2.8479 8.234
HT-1197 CTRP2 9.9595 20.2583 1.8754 10.705
KU-19-19 CTRP2 10.5152 26.0462 -0.5202 17.164
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 7.0467 8.3775 5.5693 0.7057

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clofarabine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Blinatumomab. Mature B-cell lymphoma [2A85] [12]
Mercaptopurine DMTM2IK Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Mercaptopurine. Mature B-cell lymphoma [2A85] [12]
Cytarabine DMZD5QR Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Cytarabine. Mature B-cell lymphoma [2A85] [12]
Coadministration of a Drug Treating the Disease Different from Clofarabine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [13]
Tretinoin DM49DUI Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tretinoin. Acne vulgaris [ED80] [12]
Isotretinoin DM4QTBN Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Isotretinoin. Acne vulgaris [ED80] [12]
Nicotinamide DMUPE07 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [12]
Pioglitazone DMKJ485 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Pioglitazone. Acute diabete complication [5A2Y] [12]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tagraxofusp. Acute myeloid leukaemia [2A60] [12]
Framycetin DMF8DNE Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Framycetin. Alcoholic liver disease [DB94] [12]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Clofarabine and Inotersen. Amyloidosis [5D00] [14]
Dronedarone DMA8FS5 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Dronedarone. Angina pectoris [BA40] [12]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [15]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Oxymetholone. Aplastic anaemia [3A70] [12]
Posaconazole DMUL5EW Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Posaconazole. Aspergillosis [1F20] [12]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Clofarabine and Roflumilast. Asthma [CA23] [14]
Zileuton DMVRIC2 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Zileuton. Asthma [CA23] [12]
Ofloxacin DM0VQN3 Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [16]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Kanamycin. Bacterial infection [1A00-1C4Z] [12]
Clavulanate DM2FGRT Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Clavulanate. Bacterial infection [1A00-1C4Z] [12]
Clarithromycin DM4M1SG Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Clarithromycin. Bacterial infection [1A00-1C4Z] [12]
Trovafloxacin DM6AN32 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Trovafloxacin. Bacterial infection [1A00-1C4Z] [12]
Sulfamethoxazole DMB08GE Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [12]
Sparfloxacin DMB4HCT Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [16]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Streptomycin. Bacterial infection [1A00-1C4Z] [12]
Gemifloxacin DMHT34O Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [16]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [16]
ABT-492 DMJFD2I Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [16]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Gentamicin. Bacterial infection [1A00-1C4Z] [12]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Netilmicin. Bacterial infection [1A00-1C4Z] [12]
Levofloxacin DMS60RB Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Levofloxacin. Bacterial infection [1A00-1C4Z] [12]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Tobramycin. Bacterial infection [1A00-1C4Z] [12]
Troleandomycin DMUZNIG Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Troleandomycin. Bacterial infection [1A00-1C4Z] [12]
Minocycline DMVN5OH Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Minocycline. Bacterial infection [1A00-1C4Z] [12]
Lomefloxacin DMVRH9C Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [16]
Telithromycin DMZ4P3A Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Telithromycin. Bacterial infection [1A00-1C4Z] [12]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Etidronic acid. Bone paget disease [FB85] [12]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Clofarabine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [17]
Temozolomide DMKECZD Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Temozolomide. Brain cancer [2A00] [12]
Lomustine DMMWSUL Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Lomustine. Brain cancer [2A00] [12]
Lapatinib DM3BH1Y Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Lapatinib. Breast cancer [2C60-2C6Y] [12]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and LY2835219. Breast cancer [2C60-2C6Y] [12]
Pralatrexate DMAO80I Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Pralatrexate. Breast cancer [2C60-2C6Y] [12]
Tucatinib DMBESUA Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tucatinib. Breast cancer [2C60-2C6Y] [12]
Tamoxifen DMLB0EZ Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tamoxifen. Breast cancer [2C60-2C6Y] [12]
Bosutinib DMTI8YE Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Bosutinib. Breast cancer [2C60-2C6Y] [12]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [12]
Fluoxymesterone DMUHCF1 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Fluoxymesterone. Breast cancer [2C60-2C6Y] [12]
Atorvastatin DMF28YC Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [12]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [12]
Macitentan DMP79A1 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Macitentan. Cardiovascular disease [BA00-BE2Z] [12]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Chenodiol. Cholelithiasis [DC11] [12]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Clofarabine and Iodipamide. Cholelithiasis [DC11] [18]
Phenylbutazone DMAYL0T Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Phenylbutazone. Chronic pain [MG30] [14]
Ketoprofen DMRKXPT Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ketoprofen. Chronic pain [MG30] [14]
Regorafenib DMHSY1I Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Regorafenib. Colorectal cancer [2B91] [12]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Intedanib. Colorectal cancer [2B91] [12]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Methoxyflurane. Corneal disease [9A76-9A78] [12]
Pasireotide DMHM7JS Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Pasireotide. Cushing syndrome [5A70] [12]
Ivacaftor DMZC1HS Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ivacaftor. Cystic fibrosis [CA25] [12]
Ethanol DMDRQZU Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ethanol. Cystitis [GC00] [12]
Milnacipran DMBFE74 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Milnacipran. Depression [6A70-6A7Z] [12]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [12]
Felbamate DM1V5ZS Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Felbamate. Epilepsy/seizure [8A61-8A6Z] [12]
Fosphenytoin DMOX3LB Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [12]
Ethotoin DMXWOCP Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [12]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Cannabidiol. Epileptic encephalopathy [8A62] [12]
Mefenamic acid DMK7HFI Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Mefenamic acid. Female pelvic pain [GA34] [14]
Dantrolene DM1D8XY Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Dantrolene. Fever [MG26] [12]
Itraconazole DMCR1MV Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Itraconazole. Fungal infection [1F29-1F2F] [12]
Pentamidine DMHZJCG Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Pentamidine. Fungal infection [1F29-1F2F] [12]
Terbinafine DMI6HUW Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Terbinafine. Fungal infection [1F29-1F2F] [12]
Ketoconazole DMPZI3Q Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ketoconazole. Fungal infection [1F29-1F2F] [12]
Amphotericin B DMTAJQE Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Amphotericin B. Fungal infection [1F29-1F2F] [12]
Atovaquone DMY4UMW Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Atovaquone. Fungal infection [1F29-1F2F] [12]
Sunitinib DMCBJSR Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [12]
Lamivudine DMI347A Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Lamivudine. Hepatitis virus infection [1E50-1E51] [12]
Daclatasvir DMSFK9V Moderate Decreased clearance of Clofarabine due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [14]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [12]
Isoniazid DM5JVS3 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Rifampin DMA8J1G Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [12]
Stavudine DM6DEK9 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Stavudine. Human immunodeficiency virus disease [1C60-1C62] [12]
Tipranavir DM8HJX6 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [12]
Emtricitabine DMBMUWZ Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Emtricitabine. Human immunodeficiency virus disease [1C60-1C62] [12]
Didanosine DMI2QPE Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Didanosine. Human immunodeficiency virus disease [1C60-1C62] [12]
Rilpivirine DMJ0QOW Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [12]
Abacavir DMMN36E Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Abacavir. Human immunodeficiency virus disease [1C60-1C62] [12]
Darunavir DMN3GCH Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Darunavir. Human immunodeficiency virus disease [1C60-1C62] [12]
Maraviroc DMTL94F Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [12]
Simvastatin DM30SGU Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Simvastatin. Hyper-lipoproteinaemia [5C80] [12]
Fluvastatin DM4MDJY Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Fluvastatin. Hyper-lipoproteinaemia [5C80] [12]
Fenofibrate DMFKXDY Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Fenofibrate. Hyper-lipoproteinaemia [5C80] [12]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Clofarabine and Mipomersen. Hyper-lipoproteinaemia [5C80] [19]
Rosuvastatin DMMIQ7G Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [12]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Clofarabine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [20]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Clofarabine and BMS-201038. Hyper-lipoproteinaemia [5C80] [21]
Moexipril DM26E4B Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Moexipril. Hypertension [BA00-BA04] [12]
Captopril DM458UM Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Captopril. Hypertension [BA00-BA04] [12]
Methyldopa DM5I621 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Methyldopa. Hypertension [BA00-BA04] [12]
Quinapril DMR8H31 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Quinapril. Hypertension [BA00-BA04] [12]
Lisinopril DMUOK4C Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Lisinopril. Hypertension [BA00-BA04] [12]
Tolvaptan DMIWFRL Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [12]
Pirfenidone DM6VZFQ Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Pirfenidone. Idiopathic interstitial pneumonitis [CB03] [12]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [12]
Febuxostat DMDEXQ0 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [12]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Balsalazide. Indeterminate colitis [DD72] [12]
Meclofenamic acid DM05FXR Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [14]
Ibandronate DM0QZBN Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Ibandronate. Low bone mass disorder [FB83] [12]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Clofarabine and Denosumab. Low bone mass disorder [FB83] [22]
Crizotinib DM4F29C Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Crizotinib. Lung cancer [2C25] [12]
Ceritinib DMB920Z Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ceritinib. Lung cancer [2C25] [12]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Lurbinectedin. Lung cancer [2C25] [12]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Alectinib. Lung cancer [2C25] [12]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and BIBW 2992. Lung cancer [2C25] [12]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Pralsetinib. Lung cancer [2C25] [12]
Capmatinib DMYCXKL Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Capmatinib. Lung cancer [2C25] [12]
Selpercatinib DMZR15V Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Selpercatinib. Lung cancer [2C25] [12]
Sulphadoxine DMZI2UF Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Sulphadoxine. Malaria [1F40-1F45] [12]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [12]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Idelalisib. Mature B-cell leukaemia [2A82] [23]
Moxetumomab pasudotox DMN63DZ Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [12]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and IPI-145. Mature B-cell leukaemia [2A82] [12]
Vemurafenib DM62UG5 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Vemurafenib. Melanoma [2C30] [12]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ipilimumab. Melanoma [2C30] [12]
Dacarbazine DMNPZL4 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Dacarbazine. Melanoma [2C30] [12]
Danazol DML8KTN Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Danazol. Menstrual cycle bleeding disorder [GA20] [12]
Exjade DMHPRWG Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Exjade. Mineral absorption/transport disorder [5C64] [12]
Gallium nitrate DMF9O6B Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Gallium nitrate. Mineral excesses [5B91] [12]
Riluzole DMECBWN Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Riluzole. Motor neuron disease [8B60] [12]
Carfilzomib DM48K0X Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Carfilzomib. Multiple myeloma [2A83] [12]
Panobinostat DM58WKG Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Panobinostat. Multiple myeloma [2A83] [12]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Clofarabine and Thalidomide. Multiple myeloma [2A83] [24]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tecfidera. Multiple sclerosis [8A40] [12]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Clofarabine and Siponimod. Multiple sclerosis [8A40] [13]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Clofarabine and Fingolimod. Multiple sclerosis [8A40] [25]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Clofarabine and Ozanimod. Multiple sclerosis [8A40] [14]
Fedratinib DM4ZBK6 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Fedratinib. Myeloproliferative neoplasm [2A20] [12]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Clofarabine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [26]
Bupropion DM5PCS7 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Bupropion. Nicotine use disorder [6C4A] [12]
Entrectinib DMMPTLH Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Entrectinib. Non-small cell lung cancer [2C25] [12]
Orlistat DMRJSP8 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Orlistat. Obesity [5B80-5B81] [12]
Naproxen DMZ5RGV Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Naproxen. Osteoarthritis [FA00-FA05] [14]
Carboplatin DMG281S Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Carboplatin. Ovarian cancer [2C73] [12]
Etodolac DM6WJO9 Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Etodolac. Pain [MG30-MG3Z] [14]
Diflunisal DM7EN8I Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Diflunisal. Pain [MG30-MG3Z] [14]
Ibuprofen DM8VCBE Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ibuprofen. Pain [MG30-MG3Z] [14]
ABIRATERONE DM8V75C Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and ABIRATERONE. Prostate cancer [2C82] [12]
Nilutamide DMFN07X Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Nilutamide. Prostate cancer [2C82] [12]
Bicalutamide DMZMSPF Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Bicalutamide. Prostate cancer [2C82] [12]
Ambrisentan DMD1QXW Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Ambrisentan. Pulmonary hypertension [BB01] [12]
Everolimus DM8X2EH Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Everolimus. Renal cell carcinoma [2C90] [12]
Axitinib DMGVH6N Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Axitinib. Renal cell carcinoma [2C90] [12]
Gatifloxacin DMSL679 Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [16]
Colistimethate DMZ9BMU Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Colistimethate. Respiratory infection [CA07-CA4Z] [12]
Salsalate DM13P4C Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Salsalate. Rheumatoid arthritis [FA20] [14]
Meloxicam DM2AR7L Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Meloxicam. Rheumatoid arthritis [FA20] [14]
Penicillamine DM40EF6 Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Penicillamine. Rheumatoid arthritis [FA20] [12]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tocilizumab. Rheumatoid arthritis [FA20] [12]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Clofarabine and Canakinumab. Rheumatoid arthritis [FA20] [27]
Oxaprozin DM9UB0P Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Oxaprozin. Rheumatoid arthritis [FA20] [14]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Clofarabine and Rilonacept. Rheumatoid arthritis [FA20] [27]
Flurbiprofen DMGN4BY Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Flurbiprofen. Rheumatoid arthritis [FA20] [14]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Clofarabine and Golimumab. Rheumatoid arthritis [FA20] [28]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Sulfasalazine. Rheumatoid arthritis [FA20] [12]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Sarilumab. Rheumatoid arthritis [FA20] [12]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Clofarabine and Leflunomide. Rheumatoid arthritis [FA20] [20]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Clofarabine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [29]
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [12]
PDX-101 DM6OC53 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and PDX-101. Solid tumour/cancer [2A00-2F9Z] [12]
Ifosfamide DMCT3I8 Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [12]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [12]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [12]
Pitolisant DM8RFNJ Moderate Decreased clearance of Clofarabine due to the transporter inhibition by Pitolisant. Somnolence [MG42] [14]
Telavancin DM58VQX Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [12]
Disulfiram DMCL2OK Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Disulfiram. Substance abuse [6C40] [12]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Naltrexone. Substance abuse [6C40] [12]
Fostamatinib DM6AUHV Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Fostamatinib. Thrombocytopenia [3B64] [12]
Eltrombopag DMOGFIX Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Eltrombopag. Thrombocytopenia [3B64] [12]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Lenvatinib. Thyroid cancer [2D10] [12]
Methimazole DM25FL8 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Methimazole. Thyrotoxicosis [5A02] [12]
Tizanidine DMR2IQ4 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Tizanidine. Tonus and reflex abnormality [MB47] [12]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Clofarabine and Azathioprine. Transplant rejection [NE84] [13]
Tacrolimus DMZ7XNQ Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Tacrolimus. Transplant rejection [NE84] [12]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Olsalazine. Ulcerative colitis [DD71] [12]
Cinoxacin DM4EWNS Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [16]
Nitrofurantoin DM7PQIK Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Nitrofurantoin. Urinary tract infection [GC08] [12]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Plazomicin. Urinary tract infection [GC08] [12]
Nalidixic acid DMRM0JV Minor Decreased absorption of Clofarabine due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [16]
Elagolix DMB2C0E Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Elagolix. Uterine fibroid [2E86] [12]
Amiodarone DMUTEX3 Moderate Increased risk of hepatotoxicity by the combination of Clofarabine and Amiodarone. Ventricular tachyarrhythmia [BC71] [12]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Clofarabine and Ganciclovir. Virus infection [1A24-1D9Z] [13]
Valganciclovir DMS2IUH Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Valganciclovir. Virus infection [1A24-1D9Z] [13]
Aciclovir DMYLOVR Moderate Increased risk of nephrotoxicity by the combination of Clofarabine and Aciclovir. Virus infection [1A24-1D9Z] [12]
⏷ Show the Full List of 191 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6802).
2 Clofarabine FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
7 Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
8 Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
9 FDA label of Belinostat. The 2020 official website of the U.S. Food and Drug Administration.
10 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
11 Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells. J Korean Med Sci. 2014 Nov;29(11):1464-72. doi: 10.3346/jkms.2014.29.11.1464. Epub 2014 Nov 4.
12 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
16 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
17 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
19 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
20 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
21 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
22 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
23 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
24 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
25 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
26 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
27 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
28 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
29 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]